Switzerland

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Discontinues Hydroxychloroquine Clinical Trial Based on Slow Enrollment, Remains Committed to Pandemic Research Efforts

Lead Product(s): Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 19, 2020

Details:

Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Roche Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients in Italian Study

Lead Product(s): Tocilizumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Actemra

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

Details:

Actemra did not reduce severe respiratory symptoms, intensive care visits, or death any better than standard treatments, the Italian Medicines Agency (Aifa), Italy’s drugs regulator which authorized the study.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Roche initiates Phase III Clinical Trial of Actemra/RoActemra Plus Remdesivir in Hospitalised Patients with Severe COVID-19 Pneumonia

Lead Product(s): Tocilizumab,Remdesivir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Phase III, randomised, double-blind, multicentre study (REMDACTA) will evaluate the safety and efficacy of Actemra/RoActemra plus remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Roche Actemra studies against COVID-19 could be done this month

Lead Product(s): Tocilizumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Phase III clinical trial is evaluating the safety and efficacy of tocilizumab plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia, vs placebo and standard of care.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis, Incyte will Test Jakafi in 2nd COVID-19 Study

Lead Product(s): Ruxolitinib

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

Incyte has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of ruxolitinib plus standard-of-care, compared to SoC therapy alone, in COVID-19 associated cytokine storm.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Plans COVID-19 Testing for Ilaris

Lead Product(s): Canakinumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

The CAN-COVID trial will examine the efficacy of utilizing canakinumab, to treat a type of severe immune overreaction called cytokine release syndrome in people with COVID-19 pneumonia.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Novartis Pharmaceuticals Corporation

Novartis Discontinues Hydroxychloroquine Clinical Trial Based on Slow Enrollment, Remains Committed to Pandemic Research Efforts

F. Hoffmann-La Roche

Roche Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients in Italian Study

F. Hoffmann-La Roche

Roche initiates Phase III Clinical Trial of Actemra/RoActemra Plus Remdesivir in Hospitalised Patients with Severe COVID-19 Pneumonia

F. Hoffmann-La Roche

Roche Actemra studies against COVID-19 could be done this month

Novartis Pharmaceuticals Corporation

Novartis, Incyte will Test Jakafi in 2nd COVID-19 Study

Novartis Pharmaceuticals Corporation

Novartis Plans COVID-19 Testing for Ilaris